Page 803 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

10 References

plus amikacin as empiric therapy for fever in granulocyto- requiring mechanical ventilation: a multicenter observational
penic patients with cancer. The International Antimicrobial study. Crit Care. 2011;15:R88.
Therapy Cooperative Group of the European Organization for 312. Charles PE, Tinel C, Barbar S, et al. Procalcitonin kinetics within
Research and Treatment of Cancer and the Gruppo Italiano the first days of sepsis: relationship with the appropriateness of
Malattie Ematologiche Maligne dell’Adulto Infection Program. antibiotic therapy and the outcome. Crit Care. 2009;13:R38.
Antimicrob Agents Chemother. 1996;40:1108-1115. 313. Briel M, Christ-Crain M, Young J, et al. Procalcitonin-guided
298. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam antibiotic use versus a standard approach for acute respira-
plus amikacin versus ceftazidime plus amikacin as empiric tory tract infections in primary care: study protocol for a
therapy for fever in granulocytopenic patients with cancer. The randomised controlled trial and baseline characteristics of par-
International Antimicrobial Therapy Cooperative Group of the ticipating general practitioners [ISRCTN73182671]. BMC Fam
European Organization for Research and Treatment of Cancer. Pract. 2005;6:34.
Antimicrob Agents Chemother. 1995;39:445-452. 314. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of pro-
299. Dupont H, Carbon C, Carlet J. Monotherapy with a broad- calcitonin to shorten antibiotic treatment duration in septic
spectrum beta-lactam is as effective as its combination with patients: a randomized trial. Am J Respir Crit Care Med.
an aminoglycoside in treatment of severe generalized perito- 2008;177:498-505.
nitis: a multicenter randomized controlled trial. The Severe
Generalized Peritonitis Study Group. Antimicrob Agents 315. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for
Chemother. 2000;44:2028-2033. reduced antibiotic exposure in ventilator-associated pneumo-
nia: a randomised study. Eur Respir J. 2009;34:1364-1375.
300. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. 316. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to
Intensive Care Med. 2001;27:S33-S48.
reduce patients’ exposure to antibiotics in intensive care units
301. Leibovici L, Paul M, Poznanski O, et al. Monotherapy ver- (PRORATA trial): a multicentre randomised controlled trial.
sus beta-lactam-aminoglycoside combination treatment for Lancet. 2010;375:463-474.
gram-negative bacteremia: a prospective, observational study. 317. Hochreiter M, Kohler T, Schweiger AM, et al. Procalcitonin to
Antimicrob Agents Chemother. 1997;41:1127-1133. guide duration of antibiotic therapy in intensive care patients: a
302. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy randomized prospective controlled trial. Crit Care. 2009;13:R83.
versus beta lactam-aminoglycoside combination therapy for 318. Kopterides P, Siempos II, Tsangaris I, Tsangaris A, Armaganidis
fever with neutropenia: systematic review and meta-analysis. A. Procalcitonin-guided algorithms of antibiotic therapy in the
BMJ. 2003;326:1111. intensive care unit: a systematic review and meta-analysis of
303. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications randomized controlled trials. Crit Care Med. 2010;38:2229-2241.
of beta-lactam-aminoglycoside synergism: systematic review of 319. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-
randomised trials. Int J Antimicrob Agents. 2011;37:491-503. guided algorithm reduces length of antibiotic treatment in surgical
304. Brunkhorst FM, Oppert M, Marx G, et al. Effect of empirical intensive care patients with severe sepsis: results of a prospective
treatment with moxifloxacin and meropenem vs meropenem randomized study. Langenbecks Arch Surg. 2009;394:221-226.
on sepsis-related organ dysfunction in patients with severe 320. Ioannidou E, Siempos II, Falagas ME. Administration of anti-
sepsis: a randomized trial rreatment for sepsis-related organ microbials via the respiratory tract for the treatment of patients
dysfunction. JAMA. 2012;307:2390-2399.
with nosocomial pneumonia: a meta-analysis. J Antimicrob
305. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Chemother. 2007;60:1216-1226.
Effectiveness of combination antimicrobial therapy for 321. Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH,
Pseudomonas aeruginosa bacteremia. Antimicrob Agents Rouby JJ. Lung tissue concentrations of nebulized amikacin
Chemother. 2003;47:2756-2764.
during mechanical ventilation in piglets with healthy lungs.
306. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten Am J Respir Crit Care Med. 2002;165:171-175.
MJ. Resolution of infectious parameters after antimicrobial 322. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics
therapy in patients with ventilator-associated pneumonia. Am J and ventilator-associated tracheobronchitis in the intensive care
Respir Crit Care Med. 2001;163:1371-1375. unit. Crit Care Med. 2008;36:2008-2013.
307. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of 323. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized
ventilator-associated pneumonia: prospective evaluation of the plus intravenous colistin versus intravenous colistin alone for
clinical pulmonary infection score as an early clinical predictor the treatment of ventilator-associated pneumonia: a matched
of outcome. Crit Care Med. 2003;31:676-682. case-control study. Clin Infect Dis. 2010;51:1238-1244.
308. Combes A, Figliolini C, Trouillet JL, et al. Factors predicting 324. Rattanaumpawan P, Lorsutthitham J, Ungprasert P,
ventilator-associated pneumonia recurrence. Crit Care Med. Angkasekwinai N, Thamlikitkul V. Randomized controlled
2003;31:1102-1107. trial of nebulized colistimethate sodium as adjunctive therapy
309. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of ventilator-associated pneumonia caused by gram-negative
of antibiotic therapy for ventilator-associated pneumonia in bacteria. J Antimicrob Chemother. 2010;65:2645-2649.
adults: a randomized trial. JAMA. 2003;290:2588-2598. 325. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH,
310. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Rouby JJ. Lung deposition and efficiency of nebulized amikacin
Experience with a clinical guideline for the treatment of ventila- during Escherichia coli pneumonia in ventilated piglets. Am J
tor-associated pneumonia. Crit Care Med. 2001;29:1109-1115. Respir Crit Care Med. 2002;166:1375-1381.
311. Bloos F, Marshall JC, Dellinger RP, et al. Multinational, obser- 326. Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J.
vational study of procalcitonin in ICU patients with pneumonia Pharmacokinetics and tolerability of amikacin administered as

Section04-O-ref.indd 10 1/21/2015 11:23:25 AM